Skip to navigation bar Skip to breadcrumbs Skip to page content
clear place holder
Envelope icon E-mail Updates Teal square Text size:  a A A

cobweb icon Archived: Menopausal Hormone Therapy: Preventive Medication

Original Release Date: October 2012

This version of this topic is currently archived and inactive. It should be used for historical purposes only.

Archived: Recommendation Summary

Summary of Recommendations and Evidence

(What's This?)
Postmenopausal Women

The USPSTF recommends against the use of combined estrogen and progestin for the prevention of chronic conditions in postmenopausal women.

Postmenopausal Women, Who Have Had a Hysterectomy

The USPSTF recommends against the use of estrogen for the prevention of chronic conditions in postmenopausal women who have had a hysterectomy.


This recommendation applies only to postmenopausal women who are considering hormone therapy for the primary prevention of chronic medical conditions. This is not a recommendation about the use of hormone therapy to treat menopausal symptoms, such as hot flashes or vaginal dryness; the USPSTF did not review the evidence related to this possible indication because it falls outside of the mission and scope of the USPSTF. This recommendation also does not apply to women younger than 50 years who have had surgical menopause.


Archived: Related Information for Health Professionals

There is no related information for health professionals.

Archived: Clinical Summary

Clinical summaries are one-page documents that provide guidance to primary care clinicians for using recommendations in practice.

This summary is intended for use by primary care clinicians.

Current as of: October 2012

Internet Citation: Final Update Summary: Menopausal Hormone Therapy: Preventive Medication. U.S. Preventive Services Task Force. September 2016.

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857